The role of Type I interferons in immunoregulation of breast cancer metastasis to the bone

Slaney, Clare Y.; Möller, Andreas; Hertzog, Paul J.; Parker, Belinda S.

doi:10.4161/onci.22339

Cited by 18 publications

(5 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The IFN/ISG pathway and its relation to BC have been addressed in several studies, where type I IFN or IFN response is positively correlated with outcome, including in circulation. Furthermore, it has been shown that BC patients harboring a higher expression of the IFN signature genes have better overall survival (OS) (37)(38)(39)(40)(41)(42)(43). In line with our ndings, Garg et al found that IFN is positively correlated with improved survival in ovarian and breast malignancies(44).…”

Section: Discussionsupporting

confidence: 84%

Circulating biomarkers at diagnosis correlate with distant metastases of early luminal-like breast cancer

Lambrechts

Garg

Floris³

et al. 2023

Preprint

View full text Add to dashboard Cite

There is an urgent need for new and better biomarker modalities to estimate the risk of recurrence within the luminal-like breast cancer (BC) population. Molecular diagnostic tests used in the clinic lack accuracy in identifying patients with early luminal BC who are likely to develop metastases. This study provides proof-of-concept that various liquid biopsy read-outs could serve as valuable candidates to build a multi-modal biomarker model distinguishing, already at diagnosis, between early metastasizing and non-metastasizing patients. All these blood biomarkers (chemokines, microRNAs, leukemia-inhibitory factor, osteopontin, and serum-induced functional myeloid signaling responses) can be measured in baseline plasma/serum samples and could be added to the existing prognostic factors to improve risk stratification and more patient-tailored treatment in early luminal BC.

show abstract

Section: Discussionsupporting

confidence: 84%

Circulating biomarkers at diagnosis correlate with distant metastases of early luminal-like breast cancer

Lambrechts

Garg

Floris³

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…In another study, an endogenous IFN signature predicted an increased sensitivity to Adriamycin in matched tumors compared before and after treatment (Sistigu et al, 2014). Similarly, IFN signaling was correlated with decreased incidence of metastasis in several breast cancer patient datasets in addition to being an important determinant of therapeutic response (Bidwell et al, 2012;Slaney et al, 2013). Finally, we recently identified an IFN-b gene signature, developed from transformed Human Mammary Epithelial Cells treated with IFN-b.…”

Section: Introductionmentioning

confidence: 90%

The Critical, Clinical Role of Interferon-Beta in Regulating Cancer Stem Cell Properties in Triple-Negative Breast Cancer

Doherty

Jackson

2018

DNA and Cell Biology

View full text Add to dashboard Cite

Triple-negative breast cancer (TNBC) the deadliest form of this disease currently lacks a targeted therapy and is characterized by increased risk of metastasis and presence of therapeutically resistant cancer stem cells (CSC). Recent evidence has demonstrated that the presence of an interferon (IFN)/signal transducer of activated transcription 1 (STAT1) gene signature correlates with improved therapeutic response and overall survival in TNBC patients. In agreement with these clinical observations, our recent work has demonstrated, in a cell model of TNBC that CSC have intrinsically repressed IFN signaling. Administration of IFN-β represses CSC properties, inducing a less aggressive non-CSC state. Moreover, an elevated IFN-β gene signature correlated with repressed CSC-related genes and an increased presence of tumor-infiltrating lymphocytes in TNBC specimens. We therefore propose that IFN-β be considered as a potential therapeutic option in the treatment of TNBC, to repress the CSC properties responsible for therapy failure. Future studies aim to improve methods to target delivery of IFN-β to tumors, to maximize therapeutic efficacy while minimizing systemic side effects.

show abstract

“…16 Finally, combination of IFN1 with immune therapies in the neoadjuvant setting demonstrated a clear benefit 17 further supporting additional evidence for the anti-tumorigenic role of the IFN1 pathway in breast cancers. 18,19 On another hand, clinical trial data demonstrated a very limited efficacy of pharmacological IFN1-based drugs in patients with breast cancer (reviewed in 2,20 ). Intriguingly, the IFN1-driven gene signature in patients with breast cancers was associated with resistance to chemo/radiotherapy and poor prognosis.…”

Section: Introductionmentioning

confidence: 99%

Malignant cell-specific pro-tumorigenic role of type I interferon receptor in breast cancers

Odnokoz

Peck

et al. 2020

Cancer Biology & Therapy

View full text Add to dashboard Cite

Within the microenvironment of solid tumors, stress associated with deficit of nutrients and oxygen as well as tumor-derived factors triggers the phosphorylation-dependent degradation of the IFNAR1 chain of type I interferon (IFN1) receptor and ensuing suppression of the IFN1 pathway. Here we sought to examine the importance of these events in malignant mammary cells. Expression of non-degradable IFNAR1 S526A mutant in mouse mammary adenocarcinoma cells stimulated the IFN1 pathway yet did not affect growth of these cells in vitro or ability to form subcutaneous tumors in the syngeneic mice. Remarkably, these cells exhibited a notably accelerated growth when transplanted orthotopically into mammary glands. Importantly, in human patients with either ER+ or ER-breast cancers, high levels of IFNAR1 were associated with poor prognosis. We discuss the putative mechanisms underlying the protumorigenic role of IFNAR1 in malignant breast cells.

show abstract

The role of Type I interferons in immunoregulation of breast cancer metastasis to the bone

Cited by 18 publications

References 10 publications

Circulating biomarkers at diagnosis correlate with distant metastases of early luminal-like breast cancer

Circulating biomarkers at diagnosis correlate with distant metastases of early luminal-like breast cancer

The Critical, Clinical Role of Interferon-Beta in Regulating Cancer Stem Cell Properties in Triple-Negative Breast Cancer

Malignant cell-specific pro-tumorigenic role of type I interferon receptor in breast cancers

Contact Info

Product

Resources

About